Roy Smythe, M.D., joined SomaLogic in November 2018 as Chief Executive Officer. Throughout the course of his career, Dr. Smythe has been an internationally recognized surgeon, biomedical scientist, academician, health system administrator and healthcare business entrepreneur. Dr. Smythe came to SomaLogic from Royal Philips, where he served as Global Chief Medical Officer for Strategy and Partnerships. Before joining Philips, he served as Chief Medical Officer at Valence Health, a Chicago-based healthcare company. He held the same title previously at AVIA, a healthcare technology accelerator. A highly sought-after lecturer and the author of more than 300 papers, abstracts and essays in academic, literary and humanities publications, Dr. Smythe is also currently a member of more than 20 U.S. national learned societies.
Sequencing technologies are continuously improving, making it easier to obtain more in-depth molecular information than ever before. Emerging single-cell multi-omics sequencing technologies allow the capture of multiple modalities from a cell, including its epigenome, transcriptome, epitranscriptome, and proteome. This allows research into the heterogeneity of many biological mechanisms, and insights into complex molecular mechanisms that underpin disease.